chartexchange

HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia

GlobeNewswire Inc. | Nov 19, 2026 5:00 AM EST

— SYVIK ® becomes the first novel Syk inhibitor approved in China — 

Read original article